Clinical trial · Interventional
Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer
PET Imaging of Breast Cancer Using Oncogene Expression
NCT02810873CI-TRIAL-00089293terminatedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study terminated by PI
Summary
Brief summary (as posted)
This clinical trial studies positron emission tomography imaging in using copper Cu 64 TP3805in patients with breast cancer. Diagnostic procedures, such as positron emission tomography (PET) and positron emission mammography (PEM) scan, using Cu-64-TP3805 may help doctors find and diagnose breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Carcinoma | Breast Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Copper Cu 64 TP3805 | Drug | — | UNRESOLVED |
| Fludeoxyglucose F-18 | Radiation | — | UNRESOLVED |
| Positron Emission Mammography | Device | — | UNRESOLVED |
| Positron Emission Tomography | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- F-18-FDG Whole body Scan
- description
- STAGE I: Patients with a positive biopsy and abnormal (positive) fludeoxyglucose F18-labeled PET whole-body scan undergo a whole-body copper Cu 64 TP3805-labeled PET scan.
- interventionNames
- Device: Positron Emission Mammography
- Radiation: Fludeoxyglucose F-18
- Drug: Copper Cu 64 TP3805
- type
- EXPERIMENTAL
- label
- No F-18-FDG Scan
- description
- STAGE II: Patients with a positive biopsy, but no fludeoxyglucose F18 scan undergo a breast fludeoxyglucose F18-labeled PEM Positron Emission Mammography scan followed by a breast copper Cu 64 TP3805-labeled PEM scan.
- interventionNames
- Device: Positron Emission Tomography
- Radiation: Fludeoxyglucose F-18
- Drug: Copper Cu 64 TP3805
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female * Breast cancer shown with abnormal mammogram and histology verification (stage-1 patients will also need to have a positive F-18-FDG whole-body scan) * Tumor mass of 1 cm or larger, as determined by mammography, ultrasound, or magnetic resonance imaging (MRI) * Signed informed consent form approved by the institutional review board (IRB) Exclusion Criteria: * Pregnant or lactating female * Patient with asthma
References
Publications (0)
Data not yet available
No reference posted for this study.